Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.62B
Revenue (ttm)	432.07M
Net Income (ttm)	92.88M
Shares Out	20.00M
EPS (ttm)	4.64
PE Ratio	28.25
Forward PE	26.19
Dividend	2.50 (1.91%)
Ex-Dividend Date	Sep 2, 2025

Volume	62,614
Average Volume	23,815
Open	131.50
Previous Close	131.20
Day's Range	131.00 - 134.30
52-Week Range	108.00 - 140.60
Beta	n/a
RSI	71.23
Earnings Date	Nov 12, 2025

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2024, TADAWUL:4016's revenue was 394.00 million, an increase of 16.42% compared to the previous year's 338.44 million. Earnings were 79.85 million, an increase of 21.30%.